-

07:40:02 AM

Latest ORMP Stock Market News

ORMP - Oramed Pharmaceuticals, Inc

09/15/21 8:10 AM

Nasdaq : ORMP

clinical trial

Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled over 50% of patients planned for its Phase 2

RHEA-AI

neutral

09/09/21 8:25 AM

Nasdaq : ORMP

conferences

Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present a company

RHEA-AI

neutral

08/24/21 8:25 AM

Nasdaq : ORMP

clinical trial

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled and randomized over 25% of the planned 450

RHEA-AI

neutral

08/16/21 8:25 AM

Nasdaq : ORMP

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original

RHEA-AI

neutral

08/09/21 8:40 AM

Nasdaq : ORMP

conferences

Oramed to Present at Canaccord Genuity's 41st Annual Growth Conference

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Commercial Officer Michael Rabinowitz will present a company

RHEA-AI

neutral

08/05/21 6:40 AM

Nasdaq : ORMP

conferencescovid-19

Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its majority-owned company Oravax Medical Inc.'s oral COVID-19

RHEA-AI

neutral

07/29/21 8:25 AM

Nasdaq : ORMP

management

Oramed Pharmaceuticals Appoints Chief Commercial Officer

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Michael Rabinowitz to the newly created position of

RHEA-AI

very positive

07/21/21 8:25 AM

Nasdaq : ORMP

clinical trial

Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced several updates for its majority-owned company Oravax Medical

RHEA-AI

neutral

06/22/21 8:40 AM

Nasdaq : ORMP

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it is set to join the U.S. small cap Russell 2000® and

RHEA-AI

neutral

06/08/21 8:10 AM

Nasdaq : ORMP

clinical trial

Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized over 50% of the 675 patients

RHEA-AI

neutral

ORMP Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.oramed.com
CeoNadav Kidron
Security nameOramed Pharmaceuticals, Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees12
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1185 Avenue Of The Americas, 3Rd Floor
StateNew York
CityNew York
Zip10036
CountryUS
Phone16468441164

ORMP Description:

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsulefor the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.